Clinical trials: Acquired Immune Deficiency Syndrome (AIDS)
Hiv
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
The purpose of this study is to assess the effectiveness of the FPI bundled implementation strategy in increasing HIV testing, Pre-exposure prophylaxis (PrEP) linkage (e.g., prescription) and knowledge, and condom use/access.
- Trial name
- FPI (NCT06062342)
- Testing
- FPI
- Where
- United States
- Volunteers
- 20,400 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infections
Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)
This study will test the safety and immunogenicity of an investigational Human Immunodeficiency Virus (HIV) vaccine. Immunogenicity will be measured by evaluating the immune response to several different dose levels.
- Trial name
- NCT00350623
- Testing
- MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520), MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Mental Health
Digital Star: HIV Prevention for Youth in Mental Health Treatment
Teenagers in mental health treatment are at greater risk for HIV and other sexually transmitted infections. This greater risk comes from many factors, some of which are related to poor emotion regulation and low self-confidence.
- Trial name
- DSTAR (NCT02921841)
- Testing
- D*STAR, D*HEALTH
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Rhode Island Hospital
HIV/AIDS
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression…
- Trial name
- NCT04819347
- Testing
- Albuvirtide, 3BNC117
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Frontier Biotechnologies Inc.
Hiv
Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV
Prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood exposure to HIV.
- Trial name
- AES ODEFSEY (NCT03451032)
- Testing
- Non Interventional Study
- Where
- 6 sites in France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
HIV-infection
Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500
A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach.
- Trial name
- NCT02489487
- Testing
- VM-1500, Darunavir, Ritonavir
- Where
- Thailand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Viriom
Human Immunodeficiency Virus (HIV), Mitochondrial Diseases
Mitochondria in HIV and Aging (MITO+)
Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy.
- Trial name
- (MITO+) (NCT03489421)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease; leading to varying degrees of cognitive…
- Trial name
- HANDmac (NCT01449006)
- Testing
- Maraviroc
- Where
- 2 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Bruce Brew
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy
Evaluation of Albuminuria HIV-Infected Patients
This study will examine the following: 1) how common albuminuria and proteinuria are among HIV-positive patients, 2) what causes albuminuria or proteinuria in these patients and 3) whether the condition becomes more severe over…
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria
- Trial name
- NCT00524992
- Where
- 2 sites in United States
- Volunteers
- 252 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV, AIDS
HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
Human Immunodeficiency Virus (HIV) infected patients in the HIV registries of Johns Hopkins University, University of North Carolina and Vanderbilt University will be followed in the routine clinical care to estimate the rates of…
- Trial name
- NCT01339416
- Volunteers
- 8,202 people
- Sponsor
- ViiV Healthcare
Chronic Abnormal Immune Activation in HIV/AIDS
Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients
This is a multicenter, randomized, double-blind, dose-finding, placebo-controlled study in patients with chronic HIV infection and inadequate immune restoration treated with long-term highly active antiretroviral therapy (HAART).
- Trial name
- NCT04084444
- Testing
- T8 tablet 0.5mg, T8 tablet 1mg
- Where
- 9 sites in China
- Volunteers
- 151 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Human Immunodeficiency Virus
Use of the Shang Ring Circumcision Device in Boys Below 18 Years Old in Kenya
A proof of concept study to evaluate the feasibility of using the Shang Ring, a novel male circumcision device across all childhood age groups namely infants (under 1), 1-5 age group, 6-12 age group and the 13-17 age group.
- Trial name
- NCT01891409
- Testing
- Male circumcision using the Shang Ring device
- Where
- Kenya
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- EngenderHealth
HIV (Human Immunodeficiency Virus), Metabolic Syndrome
Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
Obese HIV-positive women with Metabolic Syndrome (HIV-MS) and obese HIV-negative women with Metabolic Syndrome will be studied before and after achieving moderate (6%-8%) diet-induced weight loss.
- Conditions
- HIV (Human Immunodeficiency Virus), Metabolic Syndrome, HIV Infections
- Trial name
- NCT00857298
- Testing
- Dietary Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Candidiasis, Oral, HIV Infections
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)
- Trial name
- NCT00002293
- Testing
- Nystatin
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
HIV-1 Adults Patients, AIDS
Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients
Phase 4, single arm, open label study designed to compare the safety and efficacy of antiviral activity and immunological effect of Maraviroc in combination with Raltegravir and Darunavir/Ritonavir for treatment of triple class…
- Conditions
- HIV-1 Adults Patients, AIDS, Triple Class Failure
- Trial name
- TERCETO (NCT01013987)
- Testing
- maraviroc, Raltegravir, Darunavir/ritonavir
- Where
- Argentina
- Volunteers
- 60 people
- Sponsor
- Fundación Huésped
Human Immunodeficiency Virus (HIV)
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
The purpose of this study is to evaluate the safety and tolerability of repeat doses of T-cell immunotherapy (SB-728mR-T) following cyclophosphamide conditioning. CCR5 is a major co-receptor for HIV entry into T-cells.
- Trial name
- NCT02225665
- Testing
- SB-728mR-T, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sangamo Therapeutics
Substance Use Disorders, Hiv
Open Trial to Improve Retention in Care for Persons With HIV Who Use Substances
The open trial will examine the feasibility and acceptability of a brief, empirically-supported acceptance-based behavioral therapy intervention to promote retention in care for out-of-care people with HIV who use substances.
- Trial name
- NCT05101044
- Testing
- Acceptance-based Behavioral Therapy (ABBT) Intervention
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Brown University
Cytomegalovirus Retinitis, HIV Infections
A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS
To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial response as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives longer duration of remission than DHPG alone (i.e.
- Trial name
- NCT00001999
- Testing
- Globulin, Immune, Ganciclovir
- Where
- United States
- Sponsor
- American National Red Cross
HIV Infections, Neuropathy
Epoetin Alfa for HIV-Associated Neuropathy Trial
The purpose of this study is to evaluate the effect of epoetin alfa on HIV-associated neuropathy by measuring changes in nerve fiber density and pain ratings.
- Trial name
- NCT00528593
- Testing
- epoetin alfa
- Sponsor
- Washington University School of Medicine